MediGene AG (MDG1) Given a €19.00 Price Target at Baader Bank
A number of other research analysts also recently issued reports on the stock. Oddo Securities set a €13.00 ($15.29) price objective on shares of MediGene AG and gave the stock a buy rating in a research report on Monday, May 29th. Independent Research GmbH set a €12.00 ($14.12) target price on shares of MediGene AG and gave the stock a neutral rating in a research report on Monday, May 29th.
MediGene AG (ETR:MDG1) opened at 10.23 on Thursday. The stock has a 50 day moving average of €11.01 and a 200 day moving average of €11.81. The company’s market cap is €206.11 million. MediGene AG has a 52 week low of €6.63 and a 52 week high of €15.19.
MediGene AG Company Profile
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.